NCT04812977View on ClinicalTrials.gov

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 10, 2018

Primary Completion Date

December 10, 2018

Study Completion Date

December 10, 2018

Conditions
Central Retinal Vein Occlusion With Macular Edema
Interventions
DRUG

Group A

Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)

Trial Locations (1)

25000

Hayatabad Medical Complex, Peshawar

All Listed Sponsors
lead

Hayatabad Medical Complex

OTHER_GOV

NCT04812977 - Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter